» Articles » PMID: 12384777

Genetic Basis of Inosine Triphosphate Pyrophosphohydrolase Deficiency

Overview
Journal Hum Genet
Specialty Genetics
Date 2002 Oct 18
PMID 12384777
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Inosine triphosphate pyrophosphohydrolase (ITPase) deficiency is a common inherited condition characterized by the abnormal accumulation of inosine triphosphate (ITP) in erythrocytes. The genetic basis and pathological consequences of ITPase deficiency are unknown. We have characterized the genomic structure of the ITPA gene, showing that it has eight exons. Five single nucleotide polymorphisms were identified, three silent (138G-->A, 561G-->A, 708G-->A) and two associated with ITPase deficiency (94C-->A, IVS2+21A-->C). Homozygotes for the 94C-->A missense mutation (Pro32 to Thr) had zero erythrocyte ITPase activity, whereas 94C-->A heterozygotes averaged 22.5% of the control mean, a level of activity consistent with impaired subunit association of a dimeric enzyme. ITPase activity of IVS2+21A-->C homozygotes averaged 60% of the control mean. In order to explore further the relationship between mutations and enzyme activity, we examined the association between genotype and ITPase activity in 100 healthy controls. Ten subjects were heterozygous for 94C-->A (allele frequency: 0.06), 24 were heterozygotes for IVS2+21A-->C (allele frequency: 0.13) and two were compound heterozygous for these mutations. The activities of IVS2+21A-->C heterozygotes and 94C-->A/IVS2+21A-->C compound heterozygotes were 60% and 10%, respectively, of the normal control mean, suggesting that the intron mutation affects enzyme activity. In all cases when ITPase activity was below the normal range, one or both mutations were found. The ITPA genotype did not correspond to any identifiable red cell phenotype. A possible relationship between ITPase deficiency and increased drug toxicity of purine analogue drugs is proposed.

Citing Articles

Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients.

Salazar J, Riera P, Gordillo J, Altes A, Martinez M, Seres M Pharmacogenomics J. 2024; 24(4):20.

PMID: 38906864 DOI: 10.1038/s41397-024-00341-2.


An ITPA Enzyme with Improved Substrate Selectivity.

Burgis N, VanWormer K, Robbins D, Smith J Protein J. 2023; 43(1):62-71.

PMID: 38066288 PMC: 10901923. DOI: 10.1007/s10930-023-10162-0.


Novel ITPA variants identified by whole genome sequencing and RNA sequencing.

Omichi N, Kishita Y, Nakama M, Sasai H, Terazawa A, Kobayashi E J Hum Genet. 2023; 68(9):649-652.

PMID: 37246162 DOI: 10.1038/s10038-023-01156-y.


Polymorphisms and the Incidence of Toxicities in Children with Acute Lymphoblastic Leukemia.

Svasdisant P, Glomglao W, Siraprapapat P, Inthararujikul W, Tachavanich K, Boonthimat C Mediterr J Hematol Infect Dis. 2023; 15(1):e2023024.

PMID: 36908869 PMC: 10000882. DOI: 10.4084/MJHID.2023.024.


Pharmacogenetics of thiopurines.

Franca R, Zudeh G, Pagarin S, Rabusin M, Lucafo M, Stocco G Cancer Drug Resist. 2022; 2(2):256-270.

PMID: 35582727 PMC: 8992634. DOI: 10.20517/cdr.2019.004.